Mobile

A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 (Canagliflozin) Compared with Si...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-016525-34

A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 (Canagliflozin) Compared with Sitagliptin and Placebo in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To assess the effect of canagliflozin relative to placebo on HbA1c after 26 weeks of treatment • To assess the safety and tolerability of canagliflozin

Critère d'inclusion

  • Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy

Liens